Baibu Guanzhong Powder Veterinary Grade API is milled with a fluidised-bed opposed-jet mill using nitrogen at -10 °C to a particle size distribution not exceeding D₉₀ 75 µm, measured by laser diffraction according to ISO 13320:2020. The closed-loop milling system with cyclone separation efficiency of 99.2% is required because particles below 10 µm exhibit electrostatic adhesion to stainless steel contact surfaces and reduce yield during tablet granulation. Roller compaction is selected over wet granulation when the API fraction exceeds 30% w/w of the tablet core, because the stemonine-type alkaloid fraction is sensitive to prolonged aqueous heat above 45 °C. A Gerteis Mini-Pactor with roll force 9 kN/cm, roll gap 1.8 mm, and roll speed 3 rpm produces granules with tapped density 0.52 g/mL and Hausner ratio 1.24. Direct compression is avoided when the API fraction exceeds 40% w/w, since hopper mass flow rate decreases from 12 g/s to 6 g/s and punch sticking increases. The granulate is blended with croscarmellose sodium 2.0% w/w and sieved through 850 µm before compression on a rotary press with 12–18 kN main compression force, 4 kN pre-compression force, and turret speed 20–35 rpm. Tablet friability tested according to USP <1216> remains below 0.8% when magnesium stearate is added at 0.5% w/w and mixed for 3 min at 10 rpm; extended mixing to 20 min increases disintegration time from 12 min to 28 min because of hydrophobic film formation on the granule surface.

Dissolution performance is evaluated using USP <711> apparatus 2 with 0.1 M HCl, paddle speed 50 rpm, and medium temperature 37 °C ± 0.5 °C. Pilot-scale batches containing 2.0% w/w croscarmellose sodium reach Q ≥ 75% at 45 min, while substitution with 4.0% w/w pregelatinised starch shifts the 45 min release to 51% and increases disintegration to 26 min. Capsule filling on a dosator-type machine is run at tamping force 20–60 N and average fill weight 250 mg; granulate moisture is held below 5.0% w/w to prevent capsule shell brittleness and dosator nozzle adhesion. Identity and adulteration control for the botanical powder are carried out by microscopy and thin-layer chromatography according to USP <561>. Residual solvent limits follow VICH GL18, with ethyl acetate and ethanol in dried granulate not exceeding 5000 ppm respectively.

What Limits Aqueous Solubility and Drench Stability in Ruminant Oral Solutions?

Aqueous oral drenches prepared with this API exhibit phase separation when pH is raised above 6.8, because phloroglucinol-derived constituents in Guanzhong ionise and complex with residual tannins at neutral and alkaline conditions. The solution is therefore buffered at pH 4.2–4.6 using citric acid monohydrate 0.8% w/v and sodium citrate dihydrate 0.3% w/v. Propylene glycol at 10% v/v is added as a cosolvent to maintain clarity at 5 °C for 72 h; glycerol is not used above 5% v/v because it raises viscosity to 18 mPa·s and slows flow through an oral dosing gun. Sodium benzoate 0.1% w/v is included as a preservative, and pH is verified with a calibrated electrode after every 500 L batch. Published stability data for this exact botanical drench configuration are limited, so a stress test at 40 °C/75% RH for 6 months is required to establish site-specific shelf life. The solution should not be combined with strongly alkaline veterinary products or cationic surfactants, as flocculation and alkaloid precipitation occur above pH 7.0.

Manufacturing is completed in a 316L stainless steel jacketed tank with bottom-mounted high-shear homogeniser at 1500 rpm for 15 min, followed by in-line filtration through a 200 µm strainer to remove insoluble plant fragments. The filtered solution is filled into amber HDPE bottles with induction-sealed caps, and headspace oxygen is reduced to below 2.0% v/v by nitrogen flushing. Cleanability is verified by swab recovery of marker alkaloids at ≥70% from tank walls and filling nozzles. For food-producing ruminants, withdrawal periods and maximum residue limits are determined by the marketing authorisation holder under the relevant veterinary drug residue framework; no generic withdrawal period should be applied to this botanical API without species-specific tissue depletion studies.

For poultry water medication, the powder is blended with anhydrous glucose or lactose in a 500 L ribbon blender at 8 rpm for 15 min to a coefficient of variation below 5.0%, verified by sampling at 10 points with a sampling thief. The blend is packed in aluminium foil laminates at RH < 45% and 25 °C because the powder is hygroscopic; water uptake above 6.0% w/w causes clumping and proportional dosing pump blockage. For automatic dosing in drinking lines, the working solution is prepared at 0.5 g/L and dosed at 1.0–2.0% v/v through a Dosatron D25RE2 proportional pump. Water hardness above 300 ppm CaCO₃ induces flocculation; this is mitigated by including citric acid anhydrous 1.5% w/w in the dry blend, which lowers drinking water pH to 4.0 and maintains solubility for 24 h in standing water lines. Turbidity is monitored by a nephelometric analyser; when turbidity exceeds 5 NTU, the water line is flushed with 0.1% w/v citric acid solution before the next medication cycle.

If the API Is Filtered Aseptically for Injectable Solutions

Injectable manufacturing requires removal of insoluble plant cell debris and endotoxin from the veterinary-grade powder before terminal sterilisation is considered. The raw powder is dispersed in water for injection at 40 °C under high-shear mixing at 12000 rpm for 10 min, then cooled to 25 °C. The suspension is clarified using a stack filter train of 5 µm polypropylene, 0.45 µm PVDF, and 0.22 µm PVDF membrane cartridges meeting ASTM E1294 pore-size integrity requirements. Terminal steam sterilisation at 121 °C for 15 min causes a 12–15% loss in total stemonine-type alkaloids in pilot-scale tests; therefore aseptic filtration is preferred when the target alkaloid content is greater than 0.5 mg/mL. The filtered solution is filled in a Grade A isolator using a peristaltic pump with silicone tubing. Batch sterility is tested per Ph. Eur. 2.6.1, and bacterial endotoxins per Ph. Eur. 2.6.14 with a limit not exceeding 0.5 EU/mg. The solution contains sodium chloride 0.8% w/v, and pH is adjusted to 5.5–6.5 with 0.1 M NaOH. Published data for this specific botanical injectable configuration are limited, so particulate matter is monitored by light obscuration per Ph. Eur. 2.9.19 at 10 µm and 25 µm channels, and filter integrity is verified by bubble point before filling.

Feed-grade premixes are prepared by geometric dilution in a double-ribbon blender with 65% volume fill, 12 rpm rotation, and 10 min mixing after the final addition. The carrier is rice hull meal or calcium carbonate with moisture below 10% as specified in ISO 6496:2001; carriers above 12% moisture cause bridging in the discharge chute and non-uniform alkaloid distribution. The premix is incorporated into complete feed at 2–5 kg/tonne and mixed for 5 min in a horizontal compulsory mixer. Homogeneity is tested by collecting 10 samples with an ISO 6497-type slotted probe and requires a coefficient of variation below 5.0% for the marker alkaloid. Batch records include mixer load, mixing time, and discharge temperature because frictional heating above 35 °C in high-speed mixers increases moisture loss and static charge on the premix.

Low-temperature pelleting is run at conditioner temperature 55 °C for 15 s and die compression ratio 1:3.5. Pellet durability index after a Holmen durability tester at 30 s remains at 91% when 2.0% w/w lignosulphonate binder is added. Direct steam conditioning above 60 °C is avoided because exposure at 80 °C for 120 s reduces granule alkaloid retention from 97% to 85%. Published data for this specific feed configuration are limited, and each feed mill must validate recovery in finished feed at ±15% of the label claim. If the API is incorporated into pelleted feed rather than post-pellet spraying, the pellet line must be equipped with a post-conditioner temperature probe and sampling port for retention testing.

Thermal Degradation of Stemonine-Type Alkaloids During Fluid-Bed Granulation

Fluid-bed top-spray granulation is used for sachet powders and dispersible granules. A Glatt GPCG 5.1 with inlet air temperature 50 °C, product temperature 32–38 °C, atomising air pressure 1.5 bar, and spray rate 15–25 g/min yields granules with particle size 150–300 µm and moisture 2.5–3.5% w/w. Hypromellose binder solution 5% w/w is applied at 12% w/w of dry powder. Inlet air above 70 °C causes glass transition of the dried extract fraction and uncontrolled agglomeration; product temperature above 45 °C accelerates loss of stemonine-type alkaloids from 0.8% w/w to 0.6% w/w within 4 h in pilot stability runs. Air distributor plate blockage by fine particles is monitored by pressure drop across the plate; the threshold is 25 mbar. The finished powder is filled into stick-packs under nitrogen with residual oxygen below 2.0% v/v.

Powder sachets for direct oral administration are filled on vertical form-fill-seal equipment at 10–20 cycles/min. The powder must pass through a 500 µm sieve and flow through a filling funnel without ratholing; bulk density is stable at 0.50–0.55 g/mL after conditioning at 25 °C and 40% RH for 24 h. Electrostatic charge on the laminate inner surface is controlled to ≤2 kV to prevent powder adhesion and fill weight variation. Seal integrity is tested per ASTM F88/F88M-21 with a minimum seal strength of 15 N/25 mm. Sachets with headspace oxygen above 2.0% v/v are rejected by in-line optical oxygen sensors. Microbiological quality of the non-sterile powder is controlled per Ph. Eur. 5.1.4, with total aerobic microbial count not exceeding 10⁴ CFU/g and total yeast and mould count not exceeding 10² CFU/g.